Psilocybin and anxiety

The primary objective of this study is to evaluate the potential efficacy of a single 25 read the full info here mg oral dose of psilocybin for MDD compared to the active placebo (niacin), assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose. Psilocybin and other hallucinogens are not considered classic drugs of abuse because they do not have reinforcing properties and do not produce drug-seeking behaviors . Use tends to be episodic and is generally short-term and experimental . Tolerance occurs with repeated dosing and is thought to be due to down-regulation of 5HT2A receptors . There may also be cross-tolerance between LSD and psilocybin . Psilocybin, like other hallucinogens, is not known to cause dependence, craving, or withdrawal. Public attitudes around psychedelics are shifting: A recent Nanos Research survey, commissioned by the Canadian Psychedelic Association, found that 82 per cent of Canadians are in favour of psilocybin-assisted therapy in end-of-life illness, while 78 per cent of those polled support legalizing it to improve the quality of life for palliative and end-of-life patients.